Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather crowded. We intend to host old friends who are passing by, hang with our short people, and take note of another turning of the calendar. And what about you? Autumn is in full swing, so enjoying a drive in the great outdoors may be in order. ‘Tis also the season to start looking for the Great Pumpkin (not to be confused with that other orange one). Or you could simply make time for someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Bristol-Myers Squibb (BMY) disclosed its blockbuster Opdivo cancer drug failed to meet the main goal in a late-stage trial on patients with a type of lung cancer whose condition had relapsed after chemotherapy, Reuters says. The drug failed to extend overall survival in patients suffering from small-cell lung cancer when compared to patients already on chemotherapy. The failure to meets its main study goal comes nearly two months after U.S. regulators approved the drug to treat patients whose lung cancer had progressed despite undergoing two previous therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!